Almirall SA continues to extend its reach in dermatology, signing a research pact with Evotec AG to investigate novel therapeutics based on a new approach to cell signalling disruption. Few details of the deal were disclosed, but it will involve Evotec using its drug discovery and preclinical development platforms with funding from Almirall, with the potential for the German group to receive future milestones and royalties.
The partners said the new mechanism of action “is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.” It was identified by Evotec researchers in Toulouse, a site which Evotec took over from Sanofi
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
